ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on ...

Deciphera Pharmaceuticals is focused on the development of their multikinase inhibitor ripretinib for the treatment of gastrointestinal stromal tumor. The INSIGHT study is comparing ripretinib against ...

Deciphera Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) ...

“Onco360 is grateful for the opportunity to partner with the team at Deciphera and become a specialty pharmacy provider for QINLOCK,” said Benito Fernandez, Chief Commercial Officer. “With the ...

Deciphera Pharmaceuticals, Inc. DCPH reported second-quarter 2023 loss of 57 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents. In the year-ago quarter, DCPH had ...